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Abstract
Cardiovascular diseases are often characterized by dysfunctional endothelium. To compensate for the related lack of nitric oxide
(NO), a class of soluble guanylate cyclase (sGC) stimulators and activators have been developed with the purpose of acting
downstream of NO in the NO-sGC-cGMP cascade. These drugs have been discovered using photoaffinity labeling of sGC and
high-throughput screening of a vast number of chemical compounds. Therefore, an understanding of the integrated physiological
effects of these drugs in vivo is necessary on the path to clinical application. We have characterized the integrated hemodynamic
impact of the sGC stimulator riociguat and the activator cinaciguat in different NO-states in healthy juvenile pigs (n ¼ 30). We
assessed the vascular effects in both systemic and pulmonary circulation, the contractile effects in the right and left ventricles, and
the effects on diastolic cardiac functions. Nitric oxide-tone in these pigs were set by using the NO-blocker L-NAME and by
infusion of nitroglycerine. The studies show a more pronounced vasodilatory effect in the systemic than pulmonary circulation for
both drugs. Riociguat acts integrated with NO in an additive manner, while cinaciguat, in principle, completely blocks the
endogenous NO effect on vascular control. Neither compound demonstrated pronounced cardiac effects but had unloading
effect on both systolic and diastolic function. Thus, riociguat can potentially act in various disease states as a mean to increase NO-
tone if systemic vasodilation can be balanced. Cinaciguat is a complicated drug to apply clinically due to its almost complete lack of
integration in the NO-tone and balance.
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Introduction
Cardiovascular diseases are often characterized by reduced
production and sensitivity to nitric oxide (NO) in vascular tis-
sue, and dynamic production and effect of this compound is a
marker of a healthy vasculature. Nitric oxide is produced from
an NO-synthase action on the amino acid arginine and acts
downstream by stimulating soluble guanylate cyclase (sGC)
in various cells, in particular, vascular smooth muscle cells.1
Guanylate cyclase, in turn, catalyzes the conversion of GTP to
cGMP, an intracellular messenger acting through protein
kinase G (PKG) and thus elicits a multitude of physiological
responses including smooth muscle relaxation. The sensitivity
of sGC to NO depends on the red-ox-state of sGC. In the
physiologically reduced state, the NO-sensitivity is normal.
In the oxidized heme-free state, NO cannot stimulate sGC.2
To circumvent the need for physiological NO production
and a normal NO-affinity in the reduced sGC, a group of sub-
stances acting directly as pharmacological stimulators3 or acti-
vators4 of soluble guanylate cyclase has been developed. One
of these compounds, the NO-stimulator riociguat (Adempas), is
currently applied clinically in pulmonary hypertension.5
Although hemodynamically reasonable, the use of these com-
pounds in clinical trials of heart failure has been hampered by
extensive systemic hypotensive effects of both stimulators6 and
particularly activators.7-9 However, the recently published
VICTORIA study found a clinical benefit for the sGC
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stimulator vericiguat in patients with heart failure with reduced
ejection fraction already on established guideline heart failure
therapy.10
In theory, the sGC stimulators act directly on sGC and in
concert with NO. On the other hand, sGC activators exert its
activity independent of NO and has been found to bind primarily
to “de-hemed” sGC in its oxidized forms. As stated, oxidized
sGC is found predominantly in pathological tissues.2,5,11,12
There are many unknowns of the physiological effects and
pharmacological applications of these compounds. From their
biochemical profile, the activators should have minimal effects
in normal vasculature. However, this has not been extensively
addressed in intact, healthy animals. Furthermore, discrimina-
tion of relative effects in the pulmonary and systemic circula-
tion have received little attention and will be valuable
knowledge for their pharmacological application in various
clinical settings. Finally, the extent to which the 2 different
principal compounds interact with the NO-tone in vivo needs
further clarification.
In this study, we have compared the circulatory effects of
the sGC-stimulator riociguat, BAY 63-2521 (Bayer AG) and
the activator cinaciguat, BAY 58-2667 (Bayer AG) in healthy,
juvenile pigs. The study aimed to explore the relative systemic
and pulmonary vascular effects of these 2 pharmacological
compounds. Both drugs were applied in animals with normal,
NO blocked, or NO-stimulated endothelial function. We also
assessed whether the activator cinaciguat would, in fact, have
effects in these healthy young animals with the presumed intact
reduced form of sGC. Finally, the study aimed specifically to
clarify how both drugs act on cardiac function.
Material and Methods
Experimental Animals
Thirty castrated male domestic pigs weighing 30 + 5 kg were
adapted to the Animal Department for 5 to 7 days. They were
fasted overnight before experiments with free access to water.
The experimental protocol was approved by the local steering
committee of the National Animal Research Authority located
at the Faculty of Health Sciences, UIT, The Arctic University
of Norway. The FDF reference is 2012/55972.
Surgical Preparation and Instrumentation
The pigs were premedicated with an intramuscular injection of
20 mgkg1 ketamine (Pfizer AS) and 1 mg of atropine
(Nycomed Pharma). Anesthesia was induced by intravenous
injection of 10 mgkg1 pentobarbital sodium (Abbott) and
0.01 mgkg1 fentanyl (Hameln Pharmaceuticals). The animals
were normo-ventilated after tracheostomy. Fraction of inspired
oxygen (FiO2) was chosen to maintain partial pressure of oxy-
gen in the blood of 100 + 2 mm Hg. FiO2 ranged from 0.20 to
0.30. Normo-ventilation was defined as an arterial PaCO2 of 40
+ 2 mm Hg. A central venous catheter was placed through the
left internal jugular vein. Anesthesia was maintained
throughout the experiment by a normative continuous infusion
of 4 mgkg1 h1 pentobarbital sodium, 0.02 mgkg1 h1
fentanyl, and 0.3 mgkg1 h1 midazolam (B. Braun). Anesthe-
sia was titrated to avoid stress reactions during interventions.
The circulating volume was maintained by a 10 to 20 mLkg1
h1 continuous infusion of 0.9% NaCl supplemented with 1.25
gL1 glucose.
The animals received 2500 IU of heparin and 5 mgkg1
amiodarone (Sanofi-Synthelabo) to avoid blood clotting of
catheters and to prevent cardiac arrhythmias. Hexamethonium
chloride, trimethyl-[6-(trimethylazaniumyl)hexyl]azanium
(Sigma-Aldrich) 15 mgkg1 was administered to avoid auton-
omous reflexes and single out vascular effects during interven-
tions and measurements.13
A 7F manometer pressure-volume catheter (Millar MPVS
Ultra) was inserted through an introducer sheath via the carotid
artery into the left ventricle as proposed by Baan et al.14 The
correct position was verified using 2-dimensional (2D) echo-
cardiography and analysis of each volume segment of the
catheter. The volume of the conductance catheter was cali-
brated at each point of the experiment by 2D echocardiography
and stroke volume estimation by thermodilution. A 5F Swan-
Ganz catheter (Edwards Lifescience Corp.) was advanced into
the normal position in a pulmonary artery. A second balloon
catheter was floated from the superior caval vein into the right
ventricle for pressure measurements. Central venous pressure
was measured in the right atrium. The systemic arterial pres-
sure was assessed from a vascular catheter in the abdominal
aorta. An 8F 50 mL IABP-balloon catheter (Maquet Cardio-
vascular) was introduced into the inferior caval vein and posi-
tioned just below the right atrium for intermittent preload
reduction.
Experimental Drugs
Riociguat and cinaciguat were obtained from Chemoki
Synthesi-Tech as a dry powder. The drugs were solubilized
as described in the study by Becker et al15: pH neutral solutions
were prepared with dimethyl sulfoxide ([DMSO] Sigma-
Aldrich) and a 1:1 solution of Transcutol, diethylene glycol
ethyl ether (Sigma-Aldrich), and Cremophor, macrogolgly-
cerol ricinoleate (Sigma-Aldrich). We used 5% Transcutol and
5% Cremophor solutions, and the ratio between DMSO, Trans-
cutol, and Cremophor was 0.05:2.5:2.5. This solution was then
further diluted with 0.9 mgmL1 NaCl to a final concentration
of test drug of 0.01 to 0.1 mgmL1 of riociguat or cinaciguat,
depending on the dose to be given. The maximum DMSO
concentration was 0.02%. L-NAME, N(G)-nitro-L-arginine
methyl ester (Sigma-Aldrich), was used as an NO synthase
inhibitor16 and nitroglycerine ([NG] Takeda AS) as NO-donor.
Experimental Protocol
Four and 3 pigs were used in a dose-response study for rioci-
guat and cinaciguat, respectively (Table 1).
76 Journal of Cardiovascular Pharmacology and Therapeutics 26(1)
The following experiments were conducted using a repeated
measurements design. After instrumentation, the pigs were
allowed to rest for 30 minutes before baseline measurements.
Cinaciguat 1 mgkg1 min1 was given as a continuous
infusion and riociguat 100 mg as a bolus, L-NAME 15 mgkg1,
and NG 5 mgkg1 min1 was then given in alternating
sequences in 4 different groups, each with 5 to 6 pigs (Figure 1).
Administration form and timing of measurements were based
on human pharmacokinetic studies.17,18 Equilibration after 30
minutes was observed between each measurement. The vehicle
was given before baseline. Hemodynamic measurements were
sampled at steady state with the ventilator in expiratory pause.
Following hemodynamic measurements, the IABP-balloon in
the inferior vena cava was inflated during data sampling to
acquire pressure-volume data at different states of left ventri-
cular (LV) work.19
Registration of Data and Analysis
Data were sampled, digitized, and analyzed using ADI Lab-
Chart Pro software v 8.1.8. Cardiac output (CO) was obtained
from thermodilution with the hardware Vigilance (Medtronic).
Transthoracic echocardiography (Philips iE33) was done at all
time points to measure end-diastolic and end-systolic dia-
meters. End-diastolic volume (Ved) was calculated by Tei-
cholts formula from echocardiographic end-diastolic
diameter. End-systolic volume was calculated as the difference
between end-diastolic volume and the stroke volume derived
from the Swan-Ganz catheter. End-diastolic and systolic
volumes were used to calibrate the conductance catheter at
each time point. The time constant of relaxation was calculated
with Weiss’ method from the exponential curve fitting of the
LV pressure curve after dP/dt min (most negative pressure
development during isovolumetric relaxation of the left
ventricle). The Tau end point was set to 3 mm Hg above left
ventricular end-diastolic pressure (LVEDP). Left ventricular
stroke work (LVSW) and right ventricular stroke work
(RVSW) were calculated as the respective areas of the pres-
sure–volume relationship of the left and right ventricles, and
preload recruitable stroke work (PRSW) were calculated from
data derived from deloading of the heart as described by Burkh-
off et al.19
Statistical Analysis
All data in the main protocol have been tested to have normal
or normality like distribution. The data are expressed as mean
and SD in tables and figures. A linear mixed model20 with pig
identity as subject (random effect, including intercept) and
drug or drugs combinations as fixed effects was used to com-
pare physiological values. The best covariance structure was
found to be autoregressive, and a comparison of means was
made by least significant difference. Restricted maximum like-
lihood ratio was used for model fitting. P values <.05 were
regarded as statistically significant. All statistical analyses
were conducted in SPSS 25.0.
Results
Based on the dose–response studies, we chose the tested dose
of riociguat and cinaciguat at 100 mgkg1 and 1
mgkg1min1, respectively. At these doses, the pigs showed
a marked, but tolerable systemic vasodilatation, and remained
hemodynamic stable with mean systemic arterial pressure
(MAP) above 50 mmHg (Table 1).
Basic hemodynamic data for all experimental animals are
shown in Figures 2 and 3 (riociguat experiments) and Figures 4
and 5 (cinaciguat experiments). Also shown in these figures are
Table 1. Dose-Response Data for Riociguat and Cinaciguat.a
Riociguat, n ¼ 4
Dose in mgkg1 Before vehicle Baseline 10 20 50 100
MAP, mm Hg 89 + 22 88 + 21 87 + 22 66 + 11b 56 + 13b 50 + 9b
MPAP, mm Hg 24 + 3 25 + 3 22 + 2 23 + 5 25 + 7 25 + 8
SVR, dynes s1 cm5 1228 + 171 1066 + 248 957 + 204 760 + 180b 568 + 124b 497 + 161b
PVR, dynes s1 cm5 205 + 100 166 + 109 146 + 87 162 + 76 179 + 76 167 + 65
Cinaciguat, n ¼ 3
Dose in mgkg1min1 Before vehicle Baseline 0.01 0.05 0.1 0.50 1.00
MAP, mm Hg 99 + 20 96 + 21 94 + 22, 93 + 18 84 + 14 74 + 12b 63 + 6b
MPAP, mm Hg 20 + 2 20 + 2 20 + 3 20 + 3 20 + 4 18 + 2 18 + 2
SVR, dynes s1 cm5 1668 + 164 1630 + 199 1675 + 347 1726 + 287 1396 + 152 1179 + 251b 925 + 232b
PVR, dynes s1 cm5 146 + 34 148 + 38 184 + 72 170 + 62 176 + 116 130 + 43 134 + 8
Abbreviations: MAP, mean systemic arterial pressure; MPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular
resistance.
aValues are mean + SD. Mixed models statistics with pig identity as random effect was used. Significance levels are given between doses of test drug and before
vehicle and between doses of test drug and baseline.
bP < .05.
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the data after infusion of L-NAME and NG. The interactive
effects of riociguat or cinaciguat with NO-modulation are sum-
marized schematically in Table 2.
Interactive Effects of Riociguat and NO on Vascular Tone
Compared to vehicle, riociguat reduced the systemic vascular
resistance by 40% and induced lower systemic blood pressures.
The same dose, with an evident systemic effect, reduced pul-
monary vascular resistance by 20% but did not decrease pul-
monary systolic or mean pulmonary blood pressures. Cardiac
output was slightly increased.
L-NAME resulted in reduced CO, higher systemic and pul-
monary blood pressures, and a corresponding calculated
increase in systemic vascular resistance (SVR) and pulmonary
vascular resistance (PVR), all compatible with its known NO
blocking effect. Riociguat, given after L-NAME, increased CO,
reduced MAP, SVR, mean pulmonary arterial pressure
(MPAP), and PVR demonstrating an NO-independent vasodi-
latory effect. L-NAME administered after riociguat in separate
experiments decreased CO and increased MAP, SVR, MPAP,
and PVR, an indication that riociguat interacts with NO in an
additive manner.
Finally, nitroglycerine, given after riociguat and L-NAME,
resulted in unchanged CO, decreased MAP, SVR, systolic and
diastolic pulmonary pressures, MPAP, and PVR confirming that
NO retains its dose-dependent effect also after giving riociguat.
Interactive Effects of Cinaciguat and NO on Vascular
Tone
Introduced in untreated animals, cinaciguat lowered systemic
and pulmonary systolic, diastolic, mean, and venous blood pres-
sures. Cardiac output was slightly reduced. Also, calculated SVR
decreased, while PVR remained unchanged. Thus, cinaciguat, as
riociguat, shows no selective pulmonary vascular dilatory effect.
Cinaciguat given after the NO-blocker L-NAME induced
both systemic and pulmonary vasodilation. However,
L-NAME, given after cinaciguat, had almost no vascular effect,
indicating that the effect of cinaciguat could not be modulated
by altering NO-tone. This was confirmed by giving nitrogly-
cerine directly after cinaciguat, as this had almost no vasoac-
tive effect, as shown in Table 2 and Figures 4 and 5.
The Effects of Riociguat and Cinaciguat on Cardiac
Function
The effects of riociguat and cinaciguat on integrated cardiac
function were tested in load-dependent and independent
calculations summarized in Figure 2 and 4 and Table 2. The
Figure 1. Outline of the 4 experimental groups. Following instrumentation and baseline recordings, NO modulation was induced by alternating
administration of cinaciguat (Cina) 1 mg kg1 min1 or riociguat (Rio) 100 mg kg1 combined with L-NAME 15 mg kg1. At the end of all
protocols remaining inducible NO response was assessed by NG 5 mg kg1 min1 infusion. L-NAME indicates N(G)-nitro-L-arginine methyl
ester; NG, nitroglycerine; NO, nitric oxide.
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Figure 2. Hemodynamic effects on the systemic circulation by NO modulation using the stimulator riociguat (Rio). Left panels stacked bars
show data from the group that received Rio as the first drug, whereas right panels are from the group with primary NO-blockade using L-NAME.
Both groups received the NO donor NG as the last drug. Line plots represent the individual animals, while bars are mean values for each
combination of medications. Error bars are SD of the mean values at each point. AoPdia indicates diastolic pressure in the aorta; AoPsyst,
systolic pressure in the aorta; EDP, end-diastolic pressure; LV dP/dt max and min, maximal left ventricular pressure rises and decline; LV PRSW,
preload recruitable stroke work; LV SW, left ventricular stroke work; LV Tau, ventricular relaxation constant; MAP, mean arterial pressure in
the aorta; NG, nitroglycerine; SVR, systemic vascular resistance. Linear mixed model statistics. *P < .05, **P < .01.
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Figure 3. Hemodynamic effects on the pulmonary circulation by NO modulation using the stimulator riociguat (Rio). Left panels show data
from the group that received Rio as the first drug, whereas the right panels are from the group where the NO system was first blocked using
L-NAME. Both groups received the NO donor NG as the last drug. Line plots represent the individual animals, while bars are mean values for
each combination of medications. Error bars are SD of the mean values at each point. CO indicates cardiac output by thermodilution; PVR,
pulmonary vascular resistance, PAP sys, PAP dia and MPAP, systolic, diastolic and mean pulmonary artery pressure; RV dP/dt max, maximal right
ventricular pressure development; RV Tau, right ventricular relaxation; HR, heart rate; RV SW, right ventricular stroke work. Linear mixed
model statistics. *P < .05, **P < .01.
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Figure 4. Hemodynamic effects on the systemic circulation by NO modulation using the activator cinaciguat (Cina). Left panels show data from
the group that received Cina as the first drug. The right panels show data when the NO system was first blocked using L-NAME. Both groups
received the NO donor NG as the last drug. Line plots represent the individual animals, while bars are mean values for each combination of
medications. Error bars are SD of the mean values at each point. AoP sys, AoP dia, and MAP, systolic, diastolic, and mean aortic pressure; EDP,
end-diastolic pressure; NG, nitroglycerine; LV dP/dt max and min, maximal left ventricular pressure development and reduction; LV PRSW, left
ventricular preload recruitable stroke work; LV SW, left ventricular stroke work; LV Tau, ventricular relaxation constant; SVR, systemic vascular
resistance. Linear mixed model statistics. *P < .05, **P < .01.
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Figure 5. Hemodynamic effects on the pulmonary circulation by NO modulation using the activator cinaciguat (Cina). Left panels show data
from the group that received Cina as the first drug, whereas the right panels are from the group where the NO system was first blocked using
L-NAME. Both groups received the NO donor NG as the last drug. Line plots represent the individual animals, while bars are mean values for
each combination of medications. Error bars are SD of the mean values at each point. CO indicates cardiac output by thermodilution; HR, heart
rate; NG, nitroglycerine; PAP sys, PAP dia, and MPAP, systolic, diastolic, and mean pulmonary artery pressure; PVR, pulmonary vascular
resistance; RV dP/dt max, maximal right ventricular pressure development; RV SW, right ventricular stroke work; RV Tau, right ventricular
relaxation. Linear mixed model statistics. *P < .05, **P < .01.
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load-related parameters of time-dependent pressure develop-
ment were slightly reduced for both left and right ventricle.
However, calculating the load-independent parameters of pre-
load recruitable stroke work showed that riociguat in this dose
had a neutral effect on cardiac contractility. Cinaciguat induced
a small reduction also on the load-independent PRSW in the
left ventricle.
Both riociguat and cinaciguat demonstrated a slower maxi-
mum intraventricular pressure fall rate, expressed as dP/dt min
in the left ventricle. For the right ventricle, cinaciguat gave a
small decrease in the absolute value of dP/dt min, while rioci-
guat did not have any effect on this index. Using the Tau-index
to curve fit the pressure decay during diastole, both cinaciguat
and riociguat resulted in significantly faster relaxation of the
left ventricle compared to baseline, and both cinaciguat and
riociguat counteracted the effect on isovolumic relaxation seen
after L-NAME by again reducing the Tau index. Both cinaci-
guat and riociguat demonstrated unchanged LV end-diastolic
volumes at lower end-diastolic pressures.
Discussion
We have shown that both cinaciguat and riociguat have pro-
nounced vasodilatory properties in the normal systemic vascu-
lature. However, in these healthy juvenile pigs, these
compounds have only minor direct effects in the pulmonary
circulation. After NO-blockade with L-NAME, a vasodilatory
effect in both vasculatures was unmasked. Importantly, no
vasoactive effect of NO could be observed after cinaciguat
infusion, indicating a functional NO-blocking effect of this
compound. In contrast, NO modulation after riociguat infusion
altered vascular tone in an interactive, qualitative physiological
expected manner. The direct cardiac responses of both drugs
were dominated by their unloading effects, and only a small
possible reduction in load-independent contractility observed
from cinaciguat. The small lusitropic effect for both drugs may
also be related to the unloading effect from their vasodilation.
The interplay of riociguat and cinaciguat with the NO-
system in the pulmonary circulation has previously been









































CO þ    þ þ  NS NS þ NS NS
LVEDP NS NS NS NS NS  NS NS NS NS  NS
MAP   þþ þþ   þþþ NS  NS  
SVR   þþþþ þþþ   þþþ NS   NS NS
LVEF þ NS   þþ þþ  NS þ NS NS NS
LVSW NS  NS NS NS  NS NS  NS  NS
LV dP/dt
max
NS   NS NS  NS NS NS NS NS NS
LV dP/dt
min
þþ þþ NS NS NS þþ  NS þþ NS þþ NS
LV Tau   þþ þþþ   þþþ þ   NS NS
LVPRSW NS  þ NS   NS NS NS NS  NS
RAP   NS NS   þ NS NS NS NS NS
MPAP NS  þþþ þþ   þþþ NS  NS  NS
PVR  NS þþþþ þþþ   þþþ   NS  NS
RV dP/dt
max
NS  þ þþ   þþ NS  NS  NS
RV dP/dt
min
NS þ   þþ þþ  NS þþþ NS þþ NS
RV Tau  NS NS NS þþ NS NS NS NS NS NS NS
Abbreviations: AoPdia, diastolic pressure in the aorta; AoPsyst, systolic pressure in the aorta; CO, cardiac output; Cina, cinaciguat; Es, the end-systolic pressure-
volume relationship; LV dP/dt max, maximum rate of developed left ventricular pressure during systole; LV dP/min, maximum rate of pressure decay in the left
ventricle during diastole; LVEDV, end-diastolic volume in the left ventricle; LVEF, left ventricular ejection fraction; LVESV, end-systolic volume in the left ventricle;
LVP developed pressure, pressure difference between maximum and end-diastolic pressure in the left ventricle; LVPed, end-diastolic pressure left ventricle;
LVPmax, maximum intraventricular pressure in the left ventricle; LVPRSW, preload recruitable stroke work in the left ventricle; LVSW, left ventricular stroke
work; MAP, mean arterial pressure in the aorta; MPAP, mean pulmonary arterial pressure, NG, nitroglycerine; PAPdia, diastolic pressure in the pulmonary artery;
PAPsys, systolic pressure in the pulmonary artery; PVR, pulmonary vascular resistance; RAPmean, mean right atrial pressure; Rio, riociguat; RV dP/dt max,
maximum rise in right ventricular pressure during systole; RV dP/dt min, maximum pressure decay in the right ventricle during diastole; RVPmax, maximum
pressure in the right ventricle; RVPmin, minimum pressure in the right ventricle; RVP developed pressure, the difference between RVPmax and RVPmin; SVR,
system vascular resistance. þ/  25% change, þþ/ ¼ 25% to 50% change, þþþ/ ¼ >51% to 100% change, þþþþ/ > 100% change from
previous combination of medications
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studied primarily in pulmonary arterial hypertension (PAH)
models.21-26 These observations are somewhat in contrast with
the relative weak pulmonary effects in healthy animals
observed in our study. A possible explanation might be a dif-
ferent level of the sGC redox-forms in pathological and normal
pulmonary vessels. Soluble guanylate cyclase is upregulated in
human idiopathic pulmonary hypertension and animal models
of PAH,25 and the vasodilatory effect of both sGC stimulators
and activators is augmented by the oxidation of sGC. It is not
known what the proportion of the different oxidation levels of
sGC is in intact, healthy animals. The effects of these drugs
given intravenously in intact animals and the interactions with
NO are consequently unknown. Our study using cinaciguat
indicates that there is a functionally oxidized sGC also in the
healthy systemic circulation, but the activity seems to be low in
the pulmonary vasculature. An alternative explanation for the
small effects of these drugs in the pulmonary vasculature is the
probable normal level of nitric oxide synthase and a concomi-
tant higher activity in healthy animals compared to reduced
levels in pulmonary vascular pathology.27
In a clinical study with riociguat applied in pulmonary
hypertension secondary to diastolic heart failure, but without
increased PVR, there was no change in transpulmonary pres-
sure gradient or pulmonary vascular resistance.28 The explana-
tion for this might be a lower expression of and lower oxidation
levels of sGC in the lungs with no primary pathology, abolish-
ing any pulmonary vascular selectivity when the drug is
applied intravenously. Inhalation, in contrast to intravenous
administration of sGC-activators and stimulators, has been
shown to give selective pulmonary vasodilatation in awake
lambs with acutely thromboxane-induced pulmonary hyperten-
sion.26 Still, such an application has not to our knowledge been
tested in humans or healthy animals.
The dynamics between NO, sGC activators, sGC stimula-
tors, and sGC have been studied in cell cultures with outcomes
indicating that sGC activators can skew the redox balance
between a small pool of oxidized sGC in the direction of
increased oxidation, rendering the sGC insensitive to NO.29
An in vitro study on healthy porcine coronary arteries and rat
thoracic aortas have shown that cinaciguat has a profound
vasodilatory effect even in the absence of vascular pathology.30
In that study, cinaciguat exhibited an irreversible effect, and the
authors proposed that cinaciguat shift the red-ox-equilibrium of
sGC toward the heme-free species. This, in turn, could explain
the observed insensitivity to NO-manipulation after cinaciguat
in our study. The time span for potential recovery of this effect
is unknown.
A phase II study on cinaciguat in acutely decompensated
heart failure was stopped prematurely due to the observation
that 71% of patients experiencing adverse events, mostly hypo-
tension. The prolonged action and loss of NO-system modula-
tion seem to make cinaciguat a potent but difficult drug to
master in clinical practice. There are no ongoing patient studies
with cinaciguat,31 but there are 9 actively recruiting studies on
riociguat in scleroderma, sickle cell disease, PAH, and chronic
thromboembolic pulmonary hypertension.32 As seen from our
research, the sGC activators have profound and partly unphy-
siological effects demanding considerable preclinical assess-
ments before clinical application. There are some phase 1
studies ongoing with sGC activators in patients with chronic
kidney failure, PAH, and acquired pulmonary distress syn-
drome.33 These studies need to be monitored closely for pos-
sible adverse circulatory effects.
We did not observe any effect of riociguat on cardiac con-
tractility evaluated by preload recruitable stroke work and only
a small negative effect of cinaciguat. Studies on ischemia–
reperfusion injuries in the heart have shown cytoprotective
properties of both cinaciguat and riociguat but no fundamental
change in heart function.11,34-36 Such a protective effect can
potentially be related to myocardial calcium handling.37,38
Infusion of NO donors to the coronary circulation seems to
work in a biphasic and concentration-dependent fashion with
increased contractility and chronotropy in low normophysiolo-
gical concentrations and the opposite effect at higher concen-
trations.39 Therefore, the effect of exogenous NO through NO
donors might be hard to predict, and since the direct activation
or stimulation of sGC additionally bypasses the cGMP-
independent effects of NO, they will predictably have a differ-
ent pharmacological profile compared to endogenous NO
stimulation.39
In our study, the most pronounced diastolic effect was a
shortened LV relaxation, expressed in the Tau index. The max-
imum pressure fall rate in the left ventricle also decreased
concomitantly with the Tau index reduction indicating an
unloading effect of both riociguat and cinaciguat.40 In a recent
paper using the sGC stimulator Bay 41-8543 in an experimental
rat model of HEFPEF (Heart Failure with Preserved Ejection
Fraction), Wilck and coworkers observed a normalization of
diastolic dysfunction.41 Of particular clinical interest, the phase
3 study of Vericiguat in HEFPEF still awaits conclusion.42
Methodological Aspects
The pigs were sedated throughout the experiments with no
concomitant use of muscle relaxant. Midazolam has a negative
inotrope and chronotrope effect in high but not in clinically
relevant anesthetic doses.43 Pentobarbital have negative chron-
otropic and inotropic effects in anesthetic doses and results in
reduced blood pressure, stroke volume, and central venous
pressure.44 Furthermore, pentothal has direct effects on vascu-
lar smooth vasculature.45 The addition of Fentanyl induces no
major hemodynamic effects but attenuate pain-mediated stress
responses.46 All these effects influence critical target values in
hemodynamic experiments. The goal of the anesthesia protocol
was to create a stable hemodynamic environment for the course
of the experiment to be able to compare the different stages of
the experiment against each other. This protocol has proven to
give good stability in prolonged hemodynamic experiments in
our lab.47 Along the same line of reasoning, hexamethonium
attenuates sympathetic activation during interventions and iso-
lates the drug effects at each stage of the experiment. As a
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trade-off, however, hexamethonium blocks a normal heart-rate
response to hypotension.
The dose target for both riociguat and cinaciguat was chosen
to keep MAP above 50 mm Hg. We chose a high dose with
clear hemodynamic effects in order to induce clear discernable
effects of these drugs without the need for excessive amounts
of animals to be used in the protocols. In the main study, MAP
after cinaciguat infusion was 50 + 5 mm Hg and in the rioci-
guat group 57 + 13 (P ¼ 0.25). There was no significant
difference in SVR, PVR, or MPAP after giving riociguat or
cinaciguat. The perfusion pressure in the cinaciguat group is
closer to the limit of autoregulation of coronary perfusion pres-
sure48 than in the riociguat group and may have attenuated
cardiac performance predominantly in the cinaciguat group.
We used PRSW as a contractility index. End-systolic
pressure–volume relationship and maximum dP/dt are alterna-
tive indexes, but PRSW have been shown to be more load-
independent and more reproducible than these alternative
indexes.49,50
Conclusion
In summary, both cinaciguat and riociguat have vasodilatory
properties in the healthy systemic circulation but only a weak
effect in the pulmonary vasculature. After blocking NO pro-
duction with L-NAME, both drugs demonstrate vasodilatory
effects in both vasculatures. Furthermore, after giving cinaci-
guat NO modulation is without any effect on vascular resis-
tance, indicating a functional block of the active NO sites on all
forms of sGC. The pharmacological profile of this sGC-
activator is, therefore, indiscriminative and, as such, is a diffi-
cult drug to handle in a clinical setting. Soluble GC activators
seem to have a long way to potential clinical applications.
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